Skip to main content
Industry News
EMA accelerates review of hemophilia A gene therapy

BioMarin Pharmaceutical has been granted an accelerated assessment of its hemophilia A gene therapy valoctocogene roxaparvovec by the European Medicines Agency. An opinion from the EMA's Committee for Medicinal Products for Human Use is expected before July 2022.

Full Story: